Verici Dx PLC on Thursday said it won two key patents for its RNA signature biomarker tests Tutiva and Clarava in the US.
Shares in Verici Dx were down 8.6% to 8.00 pence each in London on Thursday afternoon.
The Cardiff-based developer of clinical diagnostics for organ transplant said Clarava is used for the assessment of prognostic risk before transplant for acute kidney transplant rejection, while Tutivia is used post-transplant.
It said the patents cover broad molecular methods for predicting and diagnosing subclinical and clinical acute rejection via algorithmic analysis of gene sets.
The patents provide protection until 2036 for Tutivia and until 2039 for Clarava. The patents underpinning Tutivia have also been previously granted across Europe, China and Australia.
Verici Dx said the two products use a weighted pattern of RNA biomarkers to assess the risk of rejection by the kidney transplant recipient. This is alongside assessing rejection earlier and more reliably than other currently available methods.
Verici Dx said that it continues to file additional patents reflecting novel refinements to its predictive RNA signatures and methodologies driven by advanced machine learning techniques.
The company added that protecting its intellectual property is ‘fundamental’ to its strategy of ‘amassing full transcriptomic data from the biological systems and interactions associated with transplant rejection’. Over the long term, this is alongside informing transplant analysis in other organs and in the broader field of immune-mediated diseases.
‘Clarava and Tutivia address a significant unmet need and seek to improve outcomes for kidney transplant patients, by providing early, actionable information for clinicians to inform treatment plans,’ Chief Executive Officer Sara Barrington.
‘These significant new patents bolster our intellectual property portfolio and protect our proprietary methods of predicting and diagnosing sub-clinical and clinical acute kidney rejection.’
On Thursday last week, Verici Dx said it successfully progressed its registration status to compliance certification to the Centers for Medicare & Medicaid for its commercial clinical operations in 45 US states.
It said will now proceed with its plan towards full accreditation in the remaining five states.
Copyright 2023 Alliance News Ltd. All Rights Reserved.
